Stem cell therapy for autism can no longer be offered as a routine or commercial treatment in India. The Union Health Ministry has reiterated that the use of stem cells for autism spectrum disorder (ASD) must remain restricted to duly approved clinical trials, putting a regulatory check on clinics offering the intervention outside the research setting.
The move is important for families exploring treatments for autism because it makes clear that stem cell therapy is not an approved standard treatment for autism in India. A person with autism can receive such an intervention only as part of an approved clinical trial and not as a routine therapy offered by a hospital or clinic.
According to Dr Manjari Tripathi, head of the department of neurology
at AIIMS, New Delhi, “The government’s move is absolutely sensible because several clinics were doing unapproved stem cell treatment which is not yet evidence-based… the highest level of evidence comes from randomised, controlled, blinded study. So, it was just being done, and patients were paying a lot of money. A helpless parent will do anything. Hence, this is absolutely a correct step.”
Meanwhile, she said, “Once these trials, which are approved by regulatory bodies, are proven, then only it should be used as a therapy.”
But What Exactly Does This Mean For Autistic People And Their Families?
Let’s first understand what autism is. Autism is a neurodevelopmental condition that affects how a child communicates, interacts and responds to the world around them. An autistic child may have difficulty with speech, social interaction or understanding social cues. Some may show repetitive behaviours, strong routines or unusual sensitivity to sounds, touch or other sensations. The symptoms and support needs can vary widely from one child to another.
The Health Ministry’s September 16 advisory is essentially a clarification of where stem cell therapy stands in autism — research, not standard care. The government has not banned research into whether stem cells could have a role in autism. Instead, it has said that any therapeutic use must take place within the framework governing clinical trials and stem cell research.
This distinction matters because stem cell therapy is often presented to patients as an advanced or regenerative treatment. However, an intervention being investigated in research does not mean that its effectiveness has been established or that it is ready to be offered routinely.
Under the new advisory, a clinic cannot offer stem cell therapy for autism as a standard treatment simply because a family is willing to pay for it. It also cannot present an unproven intervention as an established treatment for ASD.
The advisory applies to any type of stem cell used therapeutically for autism and says such use must comply with the National Guidelines for Stem Cell Research, 2017, issued jointly by the Indian Council of Medical Research and the Department of Biotechnology, as well as other applicable government requirements.
Why Has The Government Stepped In?
The advisory follows a January 30, 2026 judgment of the Supreme Court in Yash Charitable Trust & Ors. v. Union of India & Ors., which dealt with the regulation of stem cell therapy.
The case began as a public interest litigation filed in May 2022. The petition raised concerns about clinics across India promoting, prescribing and administering stem-cell “therapy” as a treatment or cure for autism spectrum disorder. The Court also recognised the situation facing families. It noted that the difficulties associated with autism can push parents and caregivers towards experimental or unproven interventions in the hope of even partial improvement.
In response to the illegal use, the government has intervened, and several experts across India have applauded the move.
Dr Rakesh Jain, paediatric neurologist at Fortis Memorial Hospital, Gurugram, welcomed the move. “Stem-cell therapy is not an established or approved routine treatment for Autism Spectrum Disorder. At present, its therapeutic use in autism should be confined to duly approved clinical trials with appropriate regulatory oversight. Families should be protected from unproven claims of cure and should be guided towards interventions supported by scientific evidence.”
In fact, the National Medical Commission has separately reinforced the same position. In its September 5 advisory, the NMC said stem cell therapy could be offered as standard clinical care only for approved indications and that unauthorised administration, prescription, promotion or advertisement beyond those indications would amount to professional misconduct.
So, Can An Autistic Person Participate In A Stem Cell Trial?
Yes, if the intervention is part of a duly approved clinical trial and the required regulatory approvals are in place.
That is very different from walking into a clinic and paying for stem cell therapy being marketed as a treatment for autism. A clinical trial is designed to answer questions about whether an intervention works, how effective it is and what risks it may carry. The fact that a treatment is being studied means those questions have not necessarily been settled.
What Happens To Clinics Offering Such Treatments?
The Health Ministry has asked state and district regulatory authorities to ensure compliance by both government and private establishments involved in stem cell research, treatment, promotion or administration.
There can also be consequences for doctors and establishments that violate the framework.
The Supreme Court has held that non-compliance can attract professional misconduct proceedings. The Clinical Establishments (Registration and Regulation) Act, 2010, also provides for penalties and, in applicable cases, “cancellation of registration”.
The NMC has asked State Medical Councils to examine complaints of violations and take disciplinary action, after due process, where professional misconduct by a registered medical practitioner is established.
